Integra LifeSciences (NASDAQ:IART) Releases Q2 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its second quarter 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.600-0.650 for the period, compared to the consensus estimate of 0.750. The company issued revenue guidance of $411.0 million-$416.0 million, compared to the consensus revenue estimate of $395.8 million. Integra LifeSciences also updated its FY 2024 guidance to 3.010-3.110 EPS.

Integra LifeSciences Trading Down 0.9 %

Integra LifeSciences stock traded down $0.23 during trading hours on Wednesday, reaching $24.85. The stock had a trading volume of 1,082,919 shares, compared to its average volume of 813,863. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The stock has a market cap of $1.95 billion, a PE ratio of 30.22, a PEG ratio of 0.87 and a beta of 1.17. Integra LifeSciences has a 52 week low of $22.36 and a 52 week high of $50.78. The company has a fifty day simple moving average of $32.95 and a 200-day simple moving average of $38.24.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.55. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business had revenue of $368.90 million for the quarter, compared to the consensus estimate of $361.96 million. During the same period in the previous year, the firm earned $0.74 EPS. The company’s quarterly revenue was down 3.2% compared to the same quarter last year. Analysts forecast that Integra LifeSciences will post 3.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IART has been the subject of several research reports. JMP Securities decreased their price target on shares of Integra LifeSciences from $49.00 to $40.00 and set a market outperform rating for the company in a research note on Tuesday. StockNews.com lowered Integra LifeSciences from a buy rating to a hold rating in a research report on Tuesday, April 30th. Wells Fargo & Company lowered Integra LifeSciences from an overweight rating to an equal weight rating and lowered their price target for the stock from $45.00 to $25.00 in a research report on Tuesday. Citigroup raised shares of Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 price objective on the stock in a research report on Wednesday, April 3rd. Finally, Truist Financial cut their price target on shares of Integra LifeSciences from $37.00 to $25.00 and set a hold rating on the stock in a report on Tuesday. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences presently has a consensus rating of Hold and an average target price of $36.80.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.